Showing posts with label SWOG trial. Show all posts
Showing posts with label SWOG trial. Show all posts
Saturday, February 06, 2010
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
Conclusion: "Despite a favorable impact of carboplatin and PLD on progression-free survival in this trial, the effect on overall survival is not statistically significant. For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
add your opinions
early stage ovarian cancer
,
hypersenitivity
,
reactions
,
SWOG trial
Subscribe to:
Posts
(
Atom
)